AST-11X / Aston Sci. - LARVOL DELTA

Aston Science attends the American Association for Cancer Research… Announcement of results from a total of 6 studies, including cancer treatment vaccine [Google translation] (MedigateNews) - "Additionally, Aston Science presented at this academic conference: immunogenicity preclinical results of AST-11X, a vaccine using KRAS non-mutated class II epitope; AST-301 (HER2 vaccine, clinical trial in gastric cancer) Preclinical results of antitumor effect for combination therapy with HER2 ADC (Phase 2 drug); Preclinical results for antitumor effect for combination therapy with AST-201 (IGFBP2 vaccine, phase 2 clinical drug) and Keytruda in ovarian cancer; Advanced solid cancer A total of six preclinical results, including the preclinical results of AST-05X, a targeted treatment targeting ISR (integrated stress response) inhibition, are scheduled to be disclosed through poster presentations."

Preclinical • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor